Filing Details
- Accession Number:
- 0001193125-21-045077
- Form Type:
- 13G Filing
- Publication Date:
- 2021-02-16 16:51:03
- Filed By:
- Alger Associates Inc
- Company:
- Puma Biotechnology Inc. (NYSE:PBYI)
- Filing Date:
- 2021-02-16
- SEC Url:
- 13G Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Alger Associates, Inc. 13-3017981 | 3,416,003 | 0 | 3,416,003 | 0 | 3,416,003 | 8.59% |
| Alger Group Holdings | 3,416,003 | 0 | 3,416,003 | 0 | 3,416,003 | 8.59% |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
Puma Biotechnology, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
74587V107
(CUSIP Number)
December 31, 2020
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☒ Rule 13d-1(b)
☐ Rule 13d-1(c)
☐ Rule 13d-1(d)
| * | The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. |
The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP No. 74587V107 |
| 1. | Names of Reporting Persons
Alger Associates, Inc. 13-3017981 | |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
| |||||
| 3. | SEC Use Only
| |||||
| 4. | Citizenship or Place of Organization
New York | |||||
| Number of Shares Beneficially Owned by Each Reporting Person With | 5. | Sole Voting Power
3,416,003 | ||||
| 6. | Shared Voting Power
0 | |||||
| 7. | Sole Dispositive Power
3,416,003 | |||||
| 8. | Shared Dispositive Power
0 | |||||
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person
3,416,003 | |||||
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
☐ | |||||
| 11. | Percent of Class Represented by Amount in Row (9)
8.59% | |||||
| 12. | Type of Reporting Person (See Instructions)
HC | |||||
2
| CUSIP No. 74587V107 |
| 1. | Names of Reporting Persons
Alger Group Holdings, LLC | |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
| |||||
| 3. | SEC Use Only
| |||||
| 4. | Citizenship or Place of Organization
Delaware | |||||
| Number of Shares Beneficially Owned by Each Reporting Person With | 5. | Sole Voting Power
3,416,003 | ||||
| 6. | Shared Voting Power
0 | |||||
| 7. | Sole Dispositive Power
3,416,003 | |||||
| 8. | Shared Dispositive Power
0 | |||||
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person
3,416,003 | |||||
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
☐ | |||||
| 11. | Percent of Class Represented by Amount in Row (9)
8.59% | |||||
| 12. | Type of Reporting Person (See Instructions)
HC | |||||
3
| Item 1. | ||||
| (a) | Name of Issuer | |||
| Puma Biotechnology, Inc. | ||||
| (b) |
Address of Issuers Principal Executive Offices 10880 Wilshire Blvd. Suite 2150 Los Angeles, CA 90024 | |||
| Item 2. | ||||
| (a) | Name of Person Filing | |||
| Alger Associates, Inc | ||||
| Alger Group Holdings, LLC | ||||
| (b) | Address of Principal Business Office or, if none, Residence | |||
| 360 Park Avenue South, New York, NY 10010 | ||||
| (c) | Citizenship | |||
| Alger Associates, Inc. New York | ||||
| Alger Group Holdings, LLC Delaware | ||||
| (d) | Title of Class of Securities | |||
| Common Stock | ||||
| (e) | CUSIP Number | |||
| 74587V107 | ||||
| Item 3. | If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | |||
| (a) | ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); | |||
| (b) | ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); | |||
| (c) | ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); | |||
| (d) | ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); | |||
| (e) | ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); | |||
| (f) | ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); | |||
| (g) | ☒ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G); | |||
| (h) | ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); | |||
| (i) | ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); | |||
| (j) | ☐ A non-U.S. institution in accordance with § 240.13d1(b)(1)(ii)(J); | |||
| (k) | ☐ Group, in accordance with § 240.13d1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d1(b)(1)(ii)(J), please specify the type of institution: | |||
4
| Item 4. | Ownership | |
|
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. | ||
| (a) | Amount beneficially owned: | |||
| 3,416,003 | ||||
| (b) | Percent of class: | |||
| 8.59% | ||||
| (c) | Number of shares as to which the person has: | |||
|
| ||||
| (i) | Sole power to vote or to direct the vote | |||
| 3,416,003 | ||||
| (ii) | Shared power to vote or to direct the vote | |||
| 0 | ||||
| (iii) | Sole power to dispose or to direct the disposition of | |||
| 3,416,003 | ||||
| (iv) | Shared power to dispose or to direct the disposition of | |||
| 0 | ||||
| Item 5. | Ownership of Five Percent or Less of a Class | |
|
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐. | ||
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person | |
|
The securities reported herein are beneficially owned by one or more open-end investment companies or other managed accounts that are investment management clients of Fred Alger Management, LLC, (FAM) and Weatherbie Capital, LLC (Weatherbie), each a registered investment adviser. FAM and Weatherbie are each a 100% owned subsidiary of Alger Group Holdings, LLC (AGH), a holding company. AGH is a 100% owned subsidiary of Alger Associates, Inc., a holding company. | ||
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person | |
|
See Exhibit A | ||
| Item 8. | Identification and Classification of Members of the Group | |
| Item 9. | Notice of Dissolution of Group | |
| Item 10. | Certification | |
5
Signature
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
| By: Alger Associates, Inc. | ||
| By: | /s/ Hal Liebes | |
| Name: | Hal Liebes | |
| Title: | Secretary | |
| Date: | February 16, 2021 | |
| By: Alger Group Holdings, LLC | ||
| By: | /s/ Hal Liebes | |
| Name: | Hal Liebes | |
| Title: | Secretary | |
| Date: | February 16, 2021 | |
6
Exhibit A
Pursuant to Item 7 of this schedule, the following lists the identity and item 3 classification of each entity that directly beneficially owns shares of the security class being reported.
Fred Alger Management, LLC IA
Weatherbie Capital, LLC IA
Joint Filing Agreement
The undersigned hereby agree that this Schedule 13G (the Schedule 13G) with respect to the common stock of Puma Biotechnology, Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to the Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other, except to the extent that it knows or has reason to believe that such information is inaccurate. It is understood and agreed that the joint filing of the Schedule 13G shall not be construed as an admission that the persons named herein constitute a group for purposes of Regulation 13D-G of the Securities Exchange Act of 1934, nor is a joint venture for purposes of the Investment Company Act of 1940.
| By: Alger Associates, Inc. | ||
| By: | /s/ Hal Liebes | |
| Name: | Hal Liebes | |
| Title: | Secretary | |
| Date: | February 16, 2021 | |
| By: Alger Group Holdings, LLC | ||
| By: | /s/ Hal Liebes | |
| Name: | Hal Liebes | |
| Title: | Secretary | |
| Date: | February 16, 2021 | |